Top Markets
Coin of the day
Clarity Pharmaceuticals Ltd Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

CU6
주식 순위 #11775
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company,... Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
주가
$1.77
마지막 동기화: 2026-08-28
시가총액
$660.45M
변동 (1일)
7.26%
변동 (1년)
-9.15%
국가
AU
거래 Clarity Pharmaceuticals Ltd (CU6)

카테고리

Clarity Pharmaceuticals Ltd (CU6)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Clarity Pharmaceuticals Ltd의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Clarity Pharmaceuticals Ltd의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율